Abstract
Her-2/neu gene amplification is an established prognostic factor in breast cancer, and Her-2/neu protein is the target of the therapeutic monoclonal antibody Herceptin. More recently, topoisomerase IIα became a new focus of breast cancer research because of its role as a target for anthracycline therapy. Therefore, we compared Her-2/neu and topoisomerase IIα amplification/deletion in a large series of advanced breast cancer using fluorescence in situ hybridization. Paraffin-embedded archival tissue from 245 patients was retrieved and assessed for Her-2/neu and topoisomerase IIα amplification/deletion by fluorescence in situ hybridization according to standard protocols. Relation to clinical data and survival was sought. A total of 245 cases were analyzed. Amplification for Her-2/neu was seen in 57 cases (23.3%), and for topoisomerase IIα in 12 cases (4.9%). Coamplification was found in 9 samples (3.7%), 3 cases (1.2%) showed amplification of topoisomerase IIα but not of Her-2/neu, and 48 samples (19.8%) displayed amplification for Her-2/neu but not for topoisomerase IIα. Correlation to the histologic type, the stage, or the grade could not be found. Only the amplification of topoisomerase IIα was associated with very poor outco...Continue Reading
References
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A GustersonR Reed
Mar 5, 1999·Breast Cancer Research and Treatment·M D PegramD J Slamon
May 29, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·P L DepowskiJ S Ross
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G PaulettiD J Slamon
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
May 14, 2005·Human Pathology·David G HicksRaymond R Tubbs
Jun 1, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GaspariniA Morabito
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Jan 30, 2007·Breast Cancer Research and Treatment·Edurne ArriolaJorge S Reis-Filho
Oct 9, 2007·Pathology Oncology Research : POR·Asli Rehber BeserNejat Dalay
May 10, 2008·Acta Oncologica·Kirsten Vang NielsenHenning T Mouridsen
Jul 1, 2008·The Oncologist·Issa J DahabrehSamuel Murray
Feb 10, 2009·Clinical Breast Cancer·Alessandra Gennari, Paolo Pronzato
Apr 30, 2009·Journal of the National Cancer Institute·F P O'MalleyK I Pritchard
Dec 1, 2009·Molecular Oncology·Kirsten Vang NielsenBent Ejlertsen
Jan 7, 2010·Journal of Cancer Research and Clinical Oncology·Christian SchindlbeckK Friese